Danny Galbraith - head of New Services and Technology Management at Merck KGaA, Darmstadt, Germany, explores the innovation bringing RNA Therapeutics to the clinic.
RNA
Innovation in the biopharmaceutical industry has always been rapid; however, this pace is accelerating with the global call to action to develop therapies to prevent and treat Covid-19. As the industry continues to look to novel modalities as a solution to Covid-19 and other diseases, a new class of therapeutic molecule is capturing attention -- nucleic acid, particularly Ribonucleic Acid (RNA).
These molecules have demonstrated several clinical mechanisms of action in the treatment of a multitude of illnesses. For example, anti-sense or interfering RNA therapies have been used in oncology treatment and the use of the RNA to act as a means of gene delivery is showing promise.